Description

The colon health focus of the Company is currently focused towards the use of high and low molecular weight carbohydrates (e.g. mannans) to: Provide fibre; Promote a healthy gut microflora; Encapsulate and remove pathogens from the gut; Provide therapeutic options for gut specific diseases (such as IBD); Promote topical healing within the gut; Provide systemic therapeutic opportunities (e.g. skin) via for example the GALT system. The structure, bioactivity and physiological properties of mannans, for example, make them advantageous with respect to healthcare compared to some other sources of carbohydrates. Animal and human faecal trials are complete where prebiotic-type efficacy and overall gut health has been proven. At this time, trials are focussed on (IBD) and blood lipid (especially cholesterol) absorption regulation from the gut. Other gut related health/disorder applications are also being developed.

 

Resource 1 - Improved Prebiotic

Resource 2 - The potential use of hydrolysed konjac glucomannan as a prebiotic

Resource 3 - Utilisation of Glucomannans for Health In Food Hydrocolloids: Characteristics, Properties and Structures

Resource 4 - The synbiotic effects of konjac glucomannan hydrolysates (GMH) and lactobacilli on the growth of Staphylococcus aureus and Salmonella typhimurium

Resource 5 - Efficacy of cellulase and mannanase hydrolysates of konjac glucomannan to promote the growth of lactic acid bacteria

Resource 6 - Mannans and health, with a special focus on glucomannans

Resource 7 - Effects of konjac glucomannan hydrolysates on the gut microflora of mice

Resource 8 - Beneficial health characteristics of native and hydrolysed konjac (Amorphophallus konjac) glucomannan

Resource 9 - Inhibition of the adhesion of Escherichia coli to human epithelial cells by carbohydrates

Resource 10 - Glucomannans and nutrition

What's new?

Formulation/sensory trials to begin with partners in 2016.